Yabao Pharmaceutical Group Co.,Ltd. (600351.SH) announced that the company has recently conducted a prudent evaluation of its SY-009 research and development project. After comprehensive consideration of multiple factors including project progress, investment risks for continued development, and future market value, the company has decided to terminate the clinical research and development work of SY-009 in order to optimize resource allocation and focus on advantageous projects in its R&D pipeline.

In accordance with relevant regulations including Enterprise Accounting Standards and based on the accounting prudence principle, the company will make a full impairment provision for the capitalized R&D amount of this project. This impairment provision will reduce the company's total profit for 2025 by 55.7933 million yuan. The aforementioned data has not been audited, and the final accounting treatment and impact on the company shall be subject to the company's disclosed 2025 annual report.